{"product_id":"biolegend-331902","title":"Biolegend, 331902, Purified anti-human CD335 (NKp46) Antibody, 100μg","description":"\u003cp\u003eCD335, also known as NKp46, is a member of the natural cytotoxicity receptor (NCR) family which triggers cytotoxicity in NK cells. CD335 is direct­ly involved in target cell recognition and lysis, and is exclusively expressed on CD3 - CD56 + NK cells, suggesting it is a universal marker for NK cells. NKp46, along with NKp30 and NKp44, is referred to as a natural cytoxicity receptor (NCR) and plays a very important role in killing virus-infected tumor cells and MHC-class I-unprotected cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: NKp46-Fc fusion protein\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Clone 9E2 has been shown to block NK activation through NKp46.6\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Nakajima H, et al. 2000. Eur. J. Immunol. 30:3309. Kalberer CP, et al. 2003. Blood 102:127. Chen Y, et al. 2007. J. Immunol. 179:2766. Jarahian M, et al. 2009. J. Virol. 83:8108. PubMed Correia DV, et al. 2011. Blood 118:992. (FC) PubMed Achdout H. et al. 2010. J. Virol. 84:3993.\u003cbr\u003e\nProduct Citations: Dorsch M, et al. 2020. Eur J Immunol. 50:656. PubMed Aarsund M, et al. 2022. Cancer Immunol Immunother. 71:2227. PubMed Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed Gadalla R, et al. 2022. STAR Protoc. 3:101643. PubMed Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed Rother S, et al. 2015. PLoS One. 10: 0135682. PubMed Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed Gao H, et al. 2021. J Virol. :. PubMed Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed Sanz–Ortega L, et al. 2019. Front Immunol. 1.85625. PubMed van Montfoort N, et al. 2018. Cell. 175:1744. PubMed Damele L, et al. 2021. Cancers (Basel). 13:. PubMed Capuano C, et al. 2020. Cancer Immunol Immunother. 69:501. PubMed Li J, et al. 2021. Haematologica. 106:3115. PubMed Jarahian M, et al. 2009. J Virol. 83:8108. PubMed Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed\u003cbr\u003e\nRRID: AB_1027637 (BioLegend Cat. No. 331902)\u003cbr\u003e\nStructure: Type I membrane glycoprotein (46 kD)\u003cbr\u003e\nDistribution: Expressed on resting and activated NK cells\u003cbr\u003e\nCell Type: NK cells\u003cbr\u003e\nBiology Area: Immunology, Innate Immunity\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Mandelboim O and Porgador A. 2001. Int. J. Biochem. Cell Biol. 33:1147. 2. Nakajima H, et al. 2000. Eur. J. Immunol. 30:3309. 3. Sivori S. 1999. Eur. J. Immunol. 29:1656.\u003cbr\u003e\nGene ID: 9437\u003cbr\u003e\nUniProt: View information about CD335 on UniProt.org\u003cbr\u003e\nClone: 9E2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: NKp46, NCR1\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862508654761,"sku":"331902","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-331902","provider":"Iright","version":"1.0","type":"link"}